niraparib and tetrachloroisophthalonitrile

To investigate the activity of niraparib in patients with germline-mutated. BRAVO was a randomized, open-label phase III trial. Eligible patients had g. After the pre-planned interim analysis, recruitment was halted on the basis of futility, noting a high degree of discordance between local and central PFS assessment in the PC arm that resulted in informative censoring. At the final analysis (median follow-up, 19.9 months), median centrally assessed PFS was 4.1 months in the niraparib arm (. Informative censoring in the control arm prevented accurate assessment of the trial hypothesis, although there was clear evidence of niraparib's activity in this patient population.

Topics: BCG Vaccine; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Germ Cells; Germ-Line Mutation; Humans; Indazoles; Nitriles; Piperidines